Sign inCreate account

Report workspace

Add to folder
NCT01077440TERMINATEDanonymous

Detection of Donor-Derived DNA in Semen Samples Among Recipients of Allogeneic Hematopoietic Stem-Cell Transplants

Sponsor

Source record

Vanderbilt University

Phase

Source record

Phase 1

Modality

AI-normalized

gene therapy

Target

AI-normalized

Donor-derived DNA in semen samples from male cancer survivors post-allogeneic hematopoietic stem cell transplantation.

Indication / condition

AI-normalized

Cancer Survivor

Intervention

Source record

DNA analysis, polymerase chain reaction, flow cytometry, laboratory biomarker analysis

Source & freshness

Source record

NCT ID

NCT01077440

Original source

ClinicalTrials.gov

Source last updated

Dec 10, 2014

Ingested at

Jun 18, 2026

Internal sync

Jun 18, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01077440

Title

Detection of Donor-Derived DNA in Semen Samples Among Recipients of Allogeneic Hematopoietic Stem-Cell Transplants

Sponsor

Vanderbilt University

Status

TERMINATED

Phase

Phase 1

Condition raw

Cancer Survivor, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Testicular Germ Cell Tumor

Condition normalized

Cancer Survivor, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Testicular Germ Cell Tumor

Modality raw

gene therapy

Modality normalized

gene therapy

Target raw

Donor-derived DNA in semen samples from male cancer survivors post-allogeneic hematopoietic stem cell transplantation.

Target normalized

Donor-derived DNA in semen samples from male cancer survivors post-allogeneic hematopoietic stem cell transplantation.

Interventions

DNA analysis, polymerase chain reaction, flow cytometry, laboratory biomarker analysis

Public preview

Source record

This study, sponsored by Vanderbilt University, aims to explore the presence of donor-derived DNA in semen samples from male cancer survivors who have undergone allogeneic hematopoietic stem cell transplantation. The findings could have significant implications for understanding genetic changes post-transplantation and identifying potential biomarkers for cancer. The market for cancer diagnostics and biomarker identification is substantial, with increasing demand for personalized medicine approaches. However, the termination of the study due to the principal investigator's departure may hinder further development and commercialization efforts. Stakeholders should assess the competitive landscape, particularly in the fields of oncology and regenerative medicine, to identify potential collaborations or alternative research avenues.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Detection of Donor-Derived DNA in Semen Samples Among Recipients of Allogeneic Hematopoietic Stem-Cell Transplants

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 18, 2026

NCT ID

NCT01077440

Status

TERMINATED

Phase

Phase 1

Sponsor

Vanderbilt University

Executive brief

Investment-Ready Snapshot

This study, sponsored by Vanderbilt University, aims to explore the presence of donor-derived DNA in semen samples from male cancer survivors who have undergone allogeneic hematopoietic stem cell transplantation. The findings could have significant implications for understanding genetic changes post-transplantation and identifying potential biomarkers for cancer. The market for cancer diagnostics and biomarker identification is substantial, with increasing demand for personalized medicine approaches. However, the termination of the study due to the principal investigator's departure may hinder further development and commercialization efforts. Stakeholders should assess the competitive landscape, particularly in the fields of oncology and regenerative medicine, to identify potential collaborations or alternative research avenues.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedDec 10, 2014
Internal syncJun 18, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01077440

Indication

Cancer Survivor

Modality

gene therapy

Target

Donor-derived DNA in semen samples from male cancer survivors post-allogeneic hematopoietic stem cell transplantation.

Intervention

DNA analysis, polymerase chain reaction, flow cytometry, laboratory biomarker analysis

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.